NCT00000976View on ClinicalTrials.gov

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

CD4-IgG

DRUG

Zidovudine

Trial Locations (3)

331361013

Univ of Miami School of Medicine, Miami

921036325

Univ of California / San Diego Treatment Ctr, San Diego

01655

Univ of Massachusetts, Worcester

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000976 - A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex | Biotech Hunter | Biotech Hunter